Peregrine Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Peregrine Pharmaceuticals, Inc. - overview
Location
Tustin, CA, US
Primary Industry
Pharmaceuticals
About
Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing and manufacturing innovative monoclonal antibody therapeutics for the treatment of cancer and viral infections.
Current Investors
Silicon Valley Bank, Oxford Finance Corporation, MidCap Financial
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.peregrineinc.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Peregrine Pharmaceuticals, Inc. - timeline of key events
Peregrine Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Apr 30, 2014 | Apr 30, 2015 | Apr 30, 2016 | Apr 30, 2017 | Apr 30, 2018 | Apr 30, 2019 | Apr 30, 2020 | Apr 30, 2021 | Apr 30, 2022 | Apr 30, 2023 | Apr 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 22,401,000 | 26,781,000 | 44,686,000 | 57,630,000 | 53,621,000 | 53,603,000 | 59,702,000 | 95,868,000 | - | - | - |
| % Revenue Growth (YoY) | - | 19.6% | 66.9% | 29.0% | (7.0%) | (0.0%) | 11.4% | 60.6% | - | - | - |
| EBITDA (USD) | (34,720,000) | (49,458,000) | (54,825,000) | (25,797,000) | (18,076,000) | (2,876,000) | (7,849,000) | 16,612,000 | - | - | - |
| Operating Income (USD) | (35,706,000) | (50,499,000) | (56,360,000) | (28,260,000) | (20,638,000) | (5,622,000) | (10,940,000) | 12,243,000 | - | - | - |
| Operating Margin | (159.4%) | (188.6%) | (126.1%) | (49.0%) | (38.5%) | (10.5%) | (18.3%) | 12.8% | - | - | - |
| % EBITDA Margin | (155.0%) | (184.7%) | (122.7%) | (44.8%) | (33.7%) | (5.4%) | (13.1%) | 17.3% | - | - | - |
| NET Income (USD) | (35,362,000) | (50,358,000) | (55,652,000) | (28,159,000) | (21,813,000) | (4,215,000) | (10,466,000) | 11,212,000 | - | - | - |
| % Net Margin | (157.9%) | (188.0%) | (124.5%) | (48.9%) | (40.7%) | (7.9%) | (17.5%) | 11.7% | - | - | - |
Peregrine Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.